RORα, a Potential Tumor Suppressor and Therapeutic Target of Breast Cancer

Jun Du, Ren XuInternational Journal of Molecular Sciences 2012 · DOI

TL;DR

This review highlights Retinoid Orphan Nuclear Receptor alpha (RORα) as a promising tumor suppressor in breast cancer. The paper details how RORα's downregulation in cancer cells leads to malignant phenotypes and suggests that restoring RORα activity could be a novel therapeutic strategy for breast cancer treatment.

What Problem Does This Paper Address?

Breast cancer remains a leading cause of cancer-related deaths worldwide, necessitating the identification of new therapeutic targets. While many nuclear receptors (NRs) are well-understood and targeted, some, like RORα, are "orphan receptors" with poorly defined roles. This paper addresses the critical need to understand the function of RORα in breast cancer, specifically investigating its potential as a tumor suppressor and a target for drug development. The authors aim to consolidate existing evidence demonstrating RORα's role in suppressing malignant characteristics of breast cancer cells and explore the molecular pathways through which it exerts these effects.

Methods

This paper is a review, synthesizing findings from numerous published studies. Therefore, it doesn't present novel experimental methods. Instead, it discusses and integrates results obtained through various techniques employed in the cited research, including:

  • Gene expression analysis: Microarray data and RT-PCR were used to assess RORα mRNA levels in cancer tissues and cell lines compared to normal tissues.
  • In vitro studies: Cell culture experiments were used to investigate the effects of RORα expression or inhibition on breast cancer cell proliferation, apoptosis, invasion, and cell cycle distribution.
  • In vivo studies: Animal models (e.g., RORα-deficient mice, xenograft models) were used to assess the role of RORα in tumor development and progression.
  • Molecular pathway analysis: Studies explored the canonical (DNA-binding) and non-canonical (post-translational modifications, protein-protein interactions) pathways through which RORα exerts its effects, including its interactions with genes like SEMA3F, Wnt/β-catenin, and p53.
  • Pharmacological studies: The use of synthetic agonists (e.g., SR1078) and potential natural ligands (e.g., melatonin) for RORα was investigated for their therapeutic potential.

Datasets

Not discussed in the paper. The paper is a review and synthesizes data from various published studies, rather than presenting new experimental datasets.

Key Insights and Ideas

  • RORα as a consistent tumor suppressor: Across multiple studies, RORα consistently appears to suppress malignant phenotypes in breast cancer cells, both in laboratory settings and in living organisms. This suggests a fundamental role in maintaining normal breast tissue function.
  • Downregulation is key: The common downregulation or hypoactivation of RORα in breast cancer tissues and cell lines, compared to normal tissue, is a critical observation. This loss of function is linked to the development and progression of the disease.
  • Dual pathway action: RORα's tumor-suppressive activities are mediated through both canonical (direct DNA binding to ROREs) and non-canonical pathways. This multifaceted mechanism highlights its complex regulatory role.
  • Interactions with critical cancer pathways: RORα influences key cellular processes by interacting with pathways like Wnt/β-catenin, p53, and NF-κB, all of which are deeply involved in cancer development and progression. Its ability to modulate these pathways underscores its significance.
  • Potential therapeutic avenues: The identification of synthetic agonists for RORα and the suggestion of melatonin as a natural ligand open exciting possibilities for developing targeted therapies.

Key Results

  • RORα downregulation in breast cancer: Microarray data indicates that RORα mRNA levels are significantly reduced in many cancer types, including breast cancer, compared to normal tissues.
  • Suppression of malignant phenotypes: Restoration of RORα expression in breast cancer cells leads to:
  • Inhibition of cell proliferation.
  • Suppression of invasive phenotypes in 3D culture.
  • Induction of apoptosis (programmed cell death).
  • Attenuated canonical Wnt/β-catenin signaling.
  • Enhanced p53-dependent apoptosis.
  • SEMA3F as a RORα target: RORα induces SEMA3F transcription, a tumor-suppressive factor, through canonical pathways, contributing to RORα's anti-invasive effects.
  • Melatonin and RORα: Melatonin, a potential natural ligand for RORα, has shown therapeutic potential in preclinical models, inducing apoptosis and inhibiting cell invasion and proliferation.

Limitations and Future Work

  • Ligand identification: While sterols like cholesterol sulfate have been implicated, a definitive natural ligand for RORα remains elusive, hindering a complete understanding of its canonical activation.
  • Non-canonical pathway mechanisms: The precise molecular mechanisms of RORα's non-canonical pathway actions require further elucidation.
  • ER-positive vs. ER-negative breast cancer: RORα's activity may differ between ER-positive and ER-negative breast cancer subtypes, and the underlying mechanisms for these differential effects need to be explored.
  • Clinical translation: While promising preclinical data exists, further research is needed to develop clinically useful RORα-specific agonists for breast cancer treatment and to test their efficacy and safety in human trials.
  • Integrated signaling view: An integrated understanding of RORα's downstream signaling, considering the crosstalk between its various pathways, is crucial for fully grasping its role in breast cancer progression.

Summary updated

Abstract

The function of the nuclear receptor (NR) in breast cancer progression has been investigated for decades. The majority of the nuclear receptors have well characterized natural ligands, but a few of them are orphan receptors for which no ligand has been identified. RORα, one member of the retinoid orphan nuclear receptor (ROR) subfamily of orphan receptors, regulates various cellular and pathological activities. RORα is commonly down-regulated and/or hypoactivated in breast cancer compared to normal mammary tissue. Expression of RORα suppresses malignant phenotypes in breast cancer cells, in vitro and in vivo. Activity of RORα can be categorized into the canonical and non-canonical nuclear receptor pathways, which in turn regulate various breast cancer cellular function, including cell proliferation, apoptosis and invasion. This information suggests that RORα is a potent tumor suppressor and a potential therapeutic target for breast cancer.
BibTeX
@article{du2012ror,
  author = {Jun Du and Ren Xu},
  title = {{RORα, a Potential Tumor Suppressor and Therapeutic Target of Breast Cancer}},
  journal = {International Journal of Molecular Sciences},
  year = {2012},
  doi = {10.3390/ijms131215755},
}
Figure